Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT04791319 · Janssen Research & Development, LLC · PHASE2 · terminated · last registry update 2023-03-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Premature Termination due to Interim Analysis (100 patients at Week 16) meeting futility.” | – | Registry record, Janssen Research & Development, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-13Results posted on the registry: Janssen Research & Development, LLC, Bermekimab + Adalimumab (NCT04988308)
- 2023-11-13Also stopped (terminated): Janssen Research & Development, LLC, Bermekimab + Adalimumab (NCT04988308)
- 2023-09-05Results posted on the registry: Janssen Research & Development, LLC, Bermekimab Monoclonal Antibody + Placebo (NCT04021862)
- 2023-07-27Results posted on the registry: Janssen Research & Development, LLC, bermekimab + placebo (NCT04019041)
- 2023-05-24Results posted on the registry: Janssen Research & Development, LLC, Bermekimab + Placebo (NCT04990440)
- 2023-05-24Also stopped (terminated): Janssen Research & Development, LLC, Bermekimab + Placebo (NCT04990440)
- 2022-03-14Results posted on the registry: Janssen Research & Development, LLC, Bermekimab Monoclonal Antibody 400 mg (NCT03512275)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision